
    
      ADAMTS13 activity will be evaluated on day 7 after the end of daily PE and every 7 days until
      ADAMTS13 activity ≥ 20% is reached. In case of persistent severe ADAMTS13 deficiency (≤ 20%),
      caplacizumab administration could be extended for a maximum of 58 days after the end of the
      daily PE period and should be accompanied by an adjusted immunosuppressive therapy as needed.
      This duration is in accordance with the HERCULES study protocol and its SmPC.
    
  